Joseph G Skeate, Nicholas J Slipek, Walker S Lahr, Shambojit Roy, Bryce J Wick, Bibekananda Kar, Jae-Woong Chang, Erin M Stelljes, Alexandria K Gilkey, Prateek P Thenge, Miechaleen D Diers, Joshua B Krueger, Ethan M Niemeyer, Cara-Lin Lonetree, Mitchell G Kluesner, Jason B Bell, Kendell Clement, Paolo P Provenzano, Branden S Moriarity, Beau R Webber
{"title":"A singular base-editing platform for polyfunctional multiplex engineering of immune cells.","authors":"Joseph G Skeate, Nicholas J Slipek, Walker S Lahr, Shambojit Roy, Bryce J Wick, Bibekananda Kar, Jae-Woong Chang, Erin M Stelljes, Alexandria K Gilkey, Prateek P Thenge, Miechaleen D Diers, Joshua B Krueger, Ethan M Niemeyer, Cara-Lin Lonetree, Mitchell G Kluesner, Jason B Bell, Kendell Clement, Paolo P Provenzano, Branden S Moriarity, Beau R Webber","doi":"10.1016/j.ymthe.2026.07.033","DOIUrl":null,"url":null,"abstract":"<p><p>Current methods to engineer antigen-specific receptors rely on randomly integrating vectors or double-strand-break-induced targeted integration, both of which pose safety risks. To implement an all-in-one tool for multiplex knockout (KO) and knockin (KI), we expand the use of base editor nickase activity to stimulate homology-directed repair (HDR) and insert clinically relevant chimeric antigen receptors (CARs) into specific loci. Through a novel single-guide RNA design strategy and a DNA template delivered by a recombinant adeno-associated virus, we enhanced the efficiency of ABE8e-stimulated HDR in human T cells. By combining KI of CD19, CD33, or mesothelin-targeting CARs with >95% quadplex gene KO (B2M/CD3E/PDCD1/CISH), we achieve single-step generation of highly functional off-the-shelf CAR T cell products with enhanced function. Importantly, we found no detectable translocations or significant off-target edits and demonstrated efficacy against multiple cancer lines and a suppressive 3D spheroid culture model. This efficient engineering process of \"Iterative Nicking for Synchronous Engineered Reprogramming of T cells\" (INSERT) establishes a safe, simplified platform for advanced therapeutic CAR T engineering.</p>","PeriodicalId":19020,"journal":{"name":"Molecular Therapy","volume":" ","pages":"5858-5871"},"PeriodicalIF":11.4000,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13673494/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ymthe.2026.07.033","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Current methods to engineer antigen-specific receptors rely on randomly integrating vectors or double-strand-break-induced targeted integration, both of which pose safety risks. To implement an all-in-one tool for multiplex knockout (KO) and knockin (KI), we expand the use of base editor nickase activity to stimulate homology-directed repair (HDR) and insert clinically relevant chimeric antigen receptors (CARs) into specific loci. Through a novel single-guide RNA design strategy and a DNA template delivered by a recombinant adeno-associated virus, we enhanced the efficiency of ABE8e-stimulated HDR in human T cells. By combining KI of CD19, CD33, or mesothelin-targeting CARs with >95% quadplex gene KO (B2M/CD3E/PDCD1/CISH), we achieve single-step generation of highly functional off-the-shelf CAR T cell products with enhanced function. Importantly, we found no detectable translocations or significant off-target edits and demonstrated efficacy against multiple cancer lines and a suppressive 3D spheroid culture model. This efficient engineering process of "Iterative Nicking for Synchronous Engineered Reprogramming of T cells" (INSERT) establishes a safe, simplified platform for advanced therapeutic CAR T engineering.
期刊介绍:
Molecular Therapy is the leading journal for research in gene transfer, vector development, stem cell manipulation, and therapeutic interventions. It covers a broad spectrum of topics including genetic and acquired disease correction, vaccine development, pre-clinical validation, safety/efficacy studies, and clinical trials. With a focus on advancing genetics, medicine, and biotechnology, Molecular Therapy publishes peer-reviewed research, reviews, and commentaries to showcase the latest advancements in the field. With an impressive impact factor of 12.4 in 2022, it continues to attract top-tier contributions.